BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1
1641 results:

  • 1. [Modern view on the problem of diagnostics of renal angiomioadenomatous tumor].
    Osmanov Y I; Kogan E A; Gadzhieva Z K; Radenska-Lopovok S G; Prochenko D D
    Urologiia; 2024 Mar; (1):92-95. PubMed ID: 38650412
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. vhl loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
    Wolf MM; Madden MZ; Arner EN; Bader JE; Ye X; Vlach L; Tigue ML; Landis MD; Jonker PB; Hatem Z; Steiner KK; Gaines DK; Reinfeld BI; Hathaway ES; Xin F; Tantawy MN; Haake SM; Jonasch E; Muir A; Weiss VL; Beckermann KE; Rathmell WK; Rathmell JC
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618956
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. vhl governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.
    Lee H; Zhuang L; Gan B
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618953
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis.
    Zhang C; Yu M; Hepperla AJ; Zhang Z; Raj R; Zhong H; Zhou J; Hu L; Fang J; Liu H; Liang Q; Jia L; Liao C; Xi S; Simon JM; Xu K; Liu Z; Nam Y; Kapur P; Zhang Q
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618952
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
    Domański P; Piętak M; Staneta S; Fortuniak W; Kruczyk B; Kobiernik A; Bakuła P; Mydlak A; Demkow T; Sikora-Kupis B; Dumnicka P; Kucharz J
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541124
    [No Abstract]    [Full Text] [Related]  

  • 6. Mice with renal-specific alterations of stem cell-associated signaling develop symptoms of chronic kidney disease but surprisingly no tumors.
    Myszczyszyn A; Popp O; Kunz S; Sporbert A; Jung S; Penning LC; Fendler A; Mertins P; Birchmeier W
    PLoS One; 2024; 19(3):e0282938. PubMed ID: 38512983
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. DCLRE1B/Apollo germline mutations associated with renal cell carcinoma impair telomere protection.
    Bories C; Lejour T; Adolphe F; Kermasson L; Couvé S; Tanguy L; Luszczewska G; Watzky M; Poillerat V; Garnier P; Groisman R; Ferlicot S; Richard S; Saparbaev M; Revy P; Gad S; Renaud F
    Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167107. PubMed ID: 38430974
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Vascular, adipose tissue, and/or calyceal invasion in clear cell tubulopapillary renal cell tumour: potentially problematic diagnostic scenarios.
    Sangoi AR; Tsai H; Harik L; Mahlow J; Tretiakova M; Williamson SR; Hirsch MS
    Histopathology; 2024 Jun; 84(7):1167-1177. PubMed ID: 38422612
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.
    Musleh Ud Din S; Streit SG; Huynh BT; Hana C; Abraham AN; Hussein A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396737
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hereditary Renal Cancer Syndromes.
    Yanus GA; Kuligina ES; Imyanitov EN
    Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
    Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
    World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. CT-derived radiomics predict the growth rate of renal tumours in von Hippel-Lindau syndrome.
    Singh S; Dehghani Firouzabadi F; Chaurasia A; Homayounieh F; Ball MW; Huda F; Turkbey EB; Linehan WM; Malayeri AA
    Clin Radiol; 2024 May; 79(5):e675-e681. PubMed ID: 38383255
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. vhl suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
    Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
    EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
    Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
    Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.
    Tian J; Luo J; Zeng X; Ke C; Wang Y; Liu Z; Li L; Zhang Y; Hu Z; Yang C
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38355278
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI.
    Yazdian Anari P; Zahergivar A; Gopal N; Chaurasia A; Lay N; Ball MW; Turkbey B; Turkbey E; Jones EC; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2024 Apr; 49(4):1202-1209. PubMed ID: 38347265
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Percutaneous microwave ablation on management of hereditary renal cell carcinoma in Von Hippel-Lindau disease.
    Chen J; Zheng L; Zhang W; Wang Z; Yu J; Liang P
    Int J Hyperthermia; 2024; 41(1):2308079. PubMed ID: 38346873
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma.
    Sainero-Alcolado L; Garde-Lapido E; Snaebjörnsson MT; Schoch S; Stevens I; Ruiz-Pérez MV; Dyrager C; Pelechano V; Axelson H; Schulze A; Arsenian-Henriksson M
    Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2310479121. PubMed ID: 38335255
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.
    Jiang Z; Wang J; Dao C; Zhu M; Li Y; Liu F; Zhao Y; Li J; Yang Y; Pan Z
    Apoptosis; 2024 Jun; 29(5-6):681-692. PubMed ID: 38281281
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 83.